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Background: TLR-2 is expressed on the surface of leucocytes, lung and liver tissue and initiates the activation of
immune response after interaction with components of the bacterial cell wall. In this experiment we investigated
whether immunostimulation with TLR-2 agonists under conditions of sterile inflammation (hemorrhagic shock (HS))
may affect the immune response and remote organ inflammation.
Methods: Male C57/BL6 mice were subjected to standardized pressure-controlled HS (MAP of 35 mmHg for 90
minutes). The TLR-2 agonist macrophage-activated lipopeptide-2 (MALP-2) was administered (i.p.) either 12 hours
prior to the induction of HS (Group MALP PT) or after the hypotensive period (90 minutes) (Group MALP T). After
six hours, plasma cytokine levels (IL-6, KC, IL-10, and MCP-1) and lung and liver MPO activity were assessed.
Results: Pre-treatment with MALP-2 resulted in a significant attenuation of the systemic pro-inflammatory (IL-6)
response (MALP PT: 0.83±0.2 ng/ml vs. MALP T: 1.7±0.09 ng/ml) (p<0.05). In comparison to the liver MPO activity,
lung MPO levels in in group MALP PT did not show differences to levels measured in MALP T mice (1.200±200
ng/mg vs. 1.800±200 ng/mg).
Conclusions: After initial inflammation, MALP-2 pre-treatment was associated with attenuated systemic immune
response after sterile stimulus. The TLR-2 agonist appears to affect sterile inflammation pathways. The exact
mechanisms should be studied further to better understand these affects.
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Trauma and hemorrhagic shock (HS) stimulate a sys-
temic release of endogenous molecules that are known
to activate the innate immune system [1]. These inflam-
matory mediators interact with Toll-like receptors
(TLR), initiate the expression of transcription factors
(e.g. NFκB) and provoke local and systemic liberation of
pro- and anti-inflammatory cytokines [1,2]. Toll-like re-
ceptor 2 (TLR-2) is expressed on the surface of immune
cells (leukocytes) and in the lung and liver. It has been
shown that bacterial cell wall components are able to
stimulate the systemic immune response through the
TLR-2 pathway [3]. The associated imbalance between
the pro- and anti-inflammatory immune system may
result in either self-destructive hyper-inflammation or
immune paralysis and sepsis [4]. Both are associated* Correspondence: rpfeifer@ukaachen.de
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reproduction in any medium, provided the orwith the development of multiple organ failure (MOF)
and high mortality rates [5,6]. Therefore, numerous
studies have aimed to identify protective mechanisms
that modulate the immune response following trauma or
sepsis [7,8].
Macrophage-activating Lipopeptide-2 (MALP-2) is a
lipopeptide and was primarily isolated from the cell wall of
Mycoplasma fermentans and was synthetized chemically
[9]. It is known to activate macrophages and other im-
mune cells (e.g. B-cells) via TLR-2 / TLR-6 heterodimers
[10]. The initial contact of MALP-2 and the immune
system initiates a pro-inflammatory immune response
[11-13]. However, desensitization of signal cascades was
also observed in studies [3]. Pre-treatment with MALP-2
in mice with sepsis and peritonitis was associated with an
attenuated immune response and reduced mortality rates
[3]. Moreover, MALP-2 administration into the respiratory
tract resulted in beneficial effects in murine pneumonia
model with Streptococcus pneumoniae [14]. All theseLtd. This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and
iginal work is properly cited.
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ment in infection models. The role of MALP-2 therapy in
sterile inflammation has not been studied so far. To this
end, we analyzed whether treatment with MALP-2 prior
and after to an inflammatory stimulus attenuates the sys-
temic inflammatory response and liver and lung inflamma-
tion in a murine hemorrhagic shock model.
Methods
Animals
Animals were housed in accordance with the regional
animal research advisory committee guidelines and the
experimental protocol has been approved by the Institu-
tional Animal Use and Care Committee. Male C57/BL6
mice (Charles Rivers Laboratories, Germany) 6 to 10
weeks old and weighing 20 to 25 g were used for this
study. Animals were maintained in the animal research
center with a 12 hour light–dark cycle and had free
access to laboratory feed and water.
Murine hemorrhagic shock model
A standardized hemorrhagic shock model was perfor-
med as described previously [15,16]. Briefly, an incision
on the left groin, dissection and cannulation of the fem-
oral artery with sterile polyethylene tubing (PE-10) was
performed. The tube was flushed with Heparin
(Ratiopharm GmbH, Germany) to prevent clotting.
Mean arterial pressure (MAP) was recorded using the
digital blood pressure monitor (TSE Systems, Bad Hom-
burg, Germany). Pressure controlled HS (MAP = 35 ± 5
mmHg, for 90 minutes) was performed by withdrawing
blood over a 15-min interval via the arterial catheter.
Animals were resuscitated over 15 minutes by transfu-
sion of the removed blood and an equal volume of 0.9%
saline. Thereafter the catheter was removed, the artery
ligated and the skin incision closed. After a recovery
phase of 4.5 hrs the animals were sacrificed.
Group distribution
Animals were randomly distributed to five experimental
groups. Each group consisted of six mice and the end-
point in all experiments was six hours. Control animals
were sacrificed directly after induction of anesthesia to
obtain physiological baseline levels, and sham animals
underwent a femoral artery catheterisation without
drawing blood. Animals subjected to hemorrhagic shock
were divided into three treatment groups (n=6). Group
HS received 100 μl (intraperitoneal (i.p.) injection of
phosphate buffered saline (PBS), Group MALP T (Treat-
ment) received an i.p. injection of MALP-2 (4 μg/kg
BW) dissolved in 100 μl of PBS after the induction of
HS, and Group MALP PT (Pre-Treatment) received an
i.p. pre-treatment of MALP-2 twelve hours prior the
initiation of HS (Figure 1). MALP is syntheticallysynthesized and purchased from MALP Research,
Braunschweig, Germany. MALP-2 was purified and di-
luted as described [17]. The stock solution was kept fro-
zen under −20° and was thawed prior to administration.
Plasma IL-6, IL-10, KC, and MCP-1
After six hours, thoracotomy (with anesthesia/ Pentobar-
bital and Isoflurane) was performed and mice were
exsanguinated via cardiac puncture. At that time point,
pronounced inflammatory response following hemor-
rhagic shock has been shown by prior studies [18]. Hep-
arinized blood samples were centrifuged at 5,000 rpm
for 10 min at 4°C. Thereafter, plasma was separated from
cellular blood components and stored at −80°C until
thawed for cytokine profile measurements. The systemic
inflammation (Plasma Interleukin (IL)-6, IL-10, mono-
cyte chemotactic protein 1 (MCP-1) and keratinocyte-
derived chemokine (KC) levels) was evaluated using
standardized ELISA kits (R&D System Inc., Mineapolis,
MN, USA). Interleukin 6 and 10 are important prognos-
tic parameters and both correlate with the systemic in-
flammatory response and injury severity [19-21]. MCP-1
was used due to recruitment and stimulation of mono-
cytes, T-cells, and neutrophils [22]. Prior investigations
have documented increased expression of MCP-1 during
aseptic inflammation [23,24]. KC (IL-8 in humans) is a
known marker of lung injury [25].
Lung and liver myeloperoxidase activity (MPO)
Lung and liver tissue were immediately snap frozen at
the experiment endpoint. Prior to the analysis, the tis-
sues were thawed and homogenized in a lysis buffer as
described by the manufacturer. MPO-enzyme-linked
immunosorbend assay kits (MPO ELISA kit, Hycultec
GmbH Beutelsbach, Germany) were used to quantify the
myeloperoxidase (MPO) activity in lung and liver tissues.
As only minor histological changes were observed fol-
lowing hemorrhagic shock models [15,16], we did not
performed histological evaluation.
Statistical analysis
Data were analysed using SPSS Version 18 (SPSS,
Chicago, IL, USA). The null hypothesis was rejected for
P< 0.05 (α =0.05). All results are expressed as the mean ±
SE of six animals per group. Group comparisons were




The systemic IL-6 release was significantly elevated in
all animals subjected to HS (Figure 2A). The i.p. injec-
tion of MALP-2 90 minutes following HS did not affect















Figure 1 Study design of experiment. Animals were subjected into three treatment groups (n=6). Group HS (Hemorrhagic Shock) received 100
μl (intraperitoneal (i.p.) injection of phosphate buffered saline (PBS) 90 minutes after induction of HS, Group MALP T (Treatment) received an i.p.
injection of MALP-2 (4 μg/kg BW) dissolved in 100 μl of PBS after the induction of HS, and Group MALP PT (Pre-Treatment) received an i.p.
pre-treatment of MALP-2 twelve hours prior the initiation of HS. Mice were sacrificed 6 hours following HS.
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significantly lower IL-6 levels (p<0.0001). Six hours fol-
lowing HS, all animals demonstrated elevated systemic
KC levels (Figure 2B). We measured a two-fold increase
of plasma KC levels by i.p. administration of MALP-2
following HS (p<0.0001).
Mice treated with MALP-2 showed a slight increase of
IL-10 (Figure 2C), but this difference was not statistically
different. Regardless of the time MALP-2 was adminis-
tered, comparable elevation of MCP-1 was observed in
both groups (Group MALP T and Group MALP PT)
(Figure 2D). The MCP-1 values were significantly lower
in untreated mice as compared to levels measured in
MALP-2 pre-treated mice and mice treated after HS.
Organ inflammation
Elevated pulmonary MPO activity was measured in mice
subjected to untreated HS and animals with MALP-2
treatment after HS (Group MALP T) (Figure 3A). Both
groups have demonstrated comparable MPO activity
levels. In pre-treated animals (Group MALP PT) MPO
activity was decreased; however, not statistically signifi-
cant as compared to either group HS and group MALP
T. Compared to control and sham, lung MPO was in-
creased by trend. The MPO activity in the liver showed a
different pattern (Figure 3B). The highest liver MPO levels
were measured in mice with MALP-2 pre-treatment
(Group MALP PT). Untreated animals have demonstrated
significantly lowed MPO activity in the liver when com-
pared with MALP-2 treated study groups.
Discussion
Numerous substances, including hormones (e.g. DHEA)
[8], cytokines (e.g. IL-10) [26,27] and diets [28] have
been identified to have immuno-modulatory effects. The
administration of the gram-negative bacterial cell wall
components prior to a second hit has been shown to di-
minish the severity of the inflammatory response [29].This phenomenon was termed endotoxin tolerance.
Similar to lipopolysaccharide (LPS), the injection of
TLR-2 ligand (MALP-2) was associated with a decrease
of pro-inflammatory mediators and immunomodulation
[3]. It has been postulated that MALP-2 attenuates the
immune response with a sufficient response for protect-
ive pathogen defense [3]. The consequences of MALP-2
treatment on the immune response were only studied in
animals with bacterial infection [3,14,30]. The aim of
these experiments was to analyze the role of MALP-2
treatment on sterile inflammation in response to HS.
This study revealed the following results: 1) Despite
single and lowest administration dose the injection of
MALP-2 prior to the induction of HS is feasible to at-
tenuate the systemic IL-6 response. 2) Organ specific in-
flammation has been observed after the pre-exposure to
MALP-2. While MPO activity within the lung tissue was
tendentially decreased in pre-treated animals, the highest
hepatic MPO levels were measured in the same group.
First, in contrast to KC values, the systemic release of
IL-6 did not increase after i.p. injection of TLR-2 ago-
nists (Group MALP T) when compared with levels in
non-treated animals with HS (Group HS). This observa-
tion is in line with previous reports [3]. Feterowski et al.
reported a slight increase in TNF-α levels and significant
elevation of KC within 2 hours after MALP-2 injection
[3]. Moreover, Reppe et al. reported comparable cytokine
patterns within the lung tissue following inhalative
MALP-2 administration [14]. Pre-exposure (12 hours) to
MALP-2 prior to the HS (Group MALP PT) was associ-
ated with a significant reduction of plasma IL-6 levels in
our study. Protective effects on the immune response
after MALP-2 treatment have been already demon-
strated in a murine sepsis model [30,31]. The adminis-
tration of MALP-2 did not affect the levels of
anti-inflammatory IL-10 in our study. These results are
in line with finding from Feterowski et al., which de-






















































































Figure 2 Comparison of plasma IL-6 (A), KC (B), IL-10 (C), and MCP-1 (D) levels in C57/BL6 mice; Animals were subjected either to
MALP-2 pre-treatment (12 hours) (Group MALP PT) or MALP-2 was administered following HS (90 minutes) (Group MALP T).
Group HS: hemorrhagic shock with PBS administration after 90 minutes. Results are expressed as means ± SE of 6 animals per group
(#<0.05 vs. Control/Sham).





















































Figure 3 Pulmonary (A) and liver (B) myeloperoxidase (MPO) activity in C57/BL6 mice; Animals were subjected either to MALP-2 pre-
treatment (12 hours) (Group MALP PT) or MALP-2 was administered following HS (90 minutes) (Group MALP T). Group HS: hemorrhagic
shock with PBS administration after 90 minutes. Results are expressed as means ± SE of 6 animals per group (#<0.05 vs. Control/Sham).
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was associated with significantly elevated MCP-1 levels
when compared to levels in mice without MALP-2 treat-
ment. Our results are in line with findings reported by
Kaufmann et al. [32]. Increased MCP-1 production ac-
companied by TNF-α was reported in human monocytes
after MALP-2 administration. Moreover, our results indi-
cate that the TLR-2 agonist appears to affect sterile inflam-
mation pathways. TLR’s recognize gram-positive and
gram-negative microbial components [33], which have
been termed Pathogen-Associated Molecular Patterns
(PAMPs), and generate a complex immune response
[33]. In addition, endogenous tissue ligands (Damage-
Associated Molecular Patterns (DAMPs)) were also
identified and are known to induce systemic inflamma-
tion [1]. Authors have hypothesized that the immune sys-
tem is mainly designed to identify threatening signals of
either infection or injury, rather than differentiate between
self and non-self [34]. However, it is still controversial
whether the acute inflammatory response is activated by
PAMPs or DAMPs through a universal pathway system. Asimilar pattern of acute inflammation after infectious and
non-infectious stimulus has been described [18]. More-
over, there is increasing evidence that DAMP-mediated in-
flammation is generated by the TLR mechanisms [35]. In
contrast, other studies pointed out DAMP specific path-
ways of the TLR activation [1,36].
Second, we identified an organ specific inflammation
following MALP-2 administration. Intraperitoneal stimu-
lation with MALP-2 12 hours prior to the initiation of HS
was associated with tendentially decreased pulmonary
MPO activity. This finding might be a consequence of the
reduced systemic pro-inflammatory response recorded in
our experiment. Moreover, this might be associated with
changes in expression and sensitivity of TLRs within peri-
toneal cavity. Studies identified slight not significant
increased TLR-4 expression within the spleen tissue after
i.p. MALP-2 administration [3]. Moreover, TLR-2 up-
regulation in the lung after inhalative MALP-2 application
has been demonstrated [14]. The reduction of the
pro-inflammatory mediators and pulmonary MPO acti-
vity might be accompanied by increased peritoneal
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compartment [14]. We observed a pronounced MPO ac-
tivity within the liver in mice with MALP-2 treatment.
MALP-2 is known to stimulate neutrophil recruitment to
the site of application [10,37]. High liver MPO activity
might be also related to increased influx of leukocytes into
the peritoneal cavity and splanchnic circulation.
Treatment with TLR-2 agonists following HS does not
attenuate the initial sterile inflammatory response in our
study. In comparison to untreated mice, treatment with
MALP-2 following HS was associated with increased
levels of KC and MCP-1 and unchanged levels of IL-6.
Moreover, the MPO activity could not be reduced. How-
ever, the therapeutic approach might be interesting in a
presence of second hit (additional surgery) or infection
(pneumonia/sepsis). Further studies are necessary to
prove the therapeutic possibilities. In addition, in this
study we focused on local and systemic inflammatory re-
sponse. We did not determine the function or damage of
organs such liver and kidney. Therefore, there is a lack of
evidence of early multiple organ failure in this study.
Our analysis should be interpreted with respect to the
following limitation: Only one time point and one treat-
ment dosage have been assessed in our study. Therefore,
no conclusions on dynamics of inflammation can be
drawn out of these data. MALP-2 is dissolved in 30%
2-propanol / water for stock solution. However, we did
not include 2-propanol to PBS in our control groups. It
has to be considered that 2-propanol may influence the
systemic inflammatory response.Conclusions
In this study, we showed that pre-treatment with TLR-2
agonists (MALP-2) may have beneficial effects in a model
of HS that mimics sterile inflammation. These protective
mechanisms were associated with reduced levels of
pro-inflammatory cytokine (IL-6). Moreover, our results
indicate that the TLR-2 agonist appears to affect sterile
inflammation pathways. The exact mechanisms should be
studied further. MALP-2 as a highly active biomolecule is
not a “dirty drug” and can be synthetized under GMP con-
ditions. It might be an option in strategies treating sterile
inflammation after HS or severe injuries.
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